| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Buprenorphine | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | | Buprenorphine | hsa00220 | Arginine biosynthesis | 4.88E-02 | 1 | P49448 | GLUD2 | More | | | Buprenorphine | hsa00250 | Alanine, aspartate and glutamate metabolism | 4.88E-02 | 1 | P49448 | GLUD2 | More | | | Buprenorphine | hsa00471 | D-Glutamine and D-glutamate metabolism | 1.65E-02 | 1 | P49448 | GLUD2 | More | | | Buprenorphine | hsa00500 | Starch and sucrose metabolism | 9.22E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Buprenorphine | hsa00730 | Thiamine metabolism | 4.66E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | | Buprenorphine | hsa00770 | Pantothenate and CoA biosynthesis | 7.90E-03 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | | Buprenorphine | hsa00910 | Nitrogen metabolism | 4.88E-02 | 1 | P49448 | GLUD2 | More | | | Buprenorphine | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.58E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | | Buprenorphine | hsa01524 | Platinum drug resistance | 1.13E-02 | 5 | P10415, Q13489, P78417, P23025, P43246 | BCL2, BIRC3, GSTO1, XPA, MSH2 | More | | | Buprenorphine | hsa03008 | Ribosome biogenesis in eukaryotes | 2.60E-03 | 5 | Q9NYH9, P78345, Q9BVP2, O15381, Q9GZY0 | UTP6, RPP38, GNL3, NVL, NXF2; NXF2B | More | | | Buprenorphine | hsa03013 | RNA transport | 2.29E-04 | 13 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, TACC3, FXR1 | More | | | Buprenorphine | hsa03020 | RNA polymerase | 4.40E-02 | 2 | P24928, P62487 | POLR2A, POLR2G | More | | | Buprenorphine | hsa03040 | Spliceosome | 5.79E-03 | 7 | Q14562, O43143, O60508, Q99633, Q13595, Q01130, Q9UMS4 | DHX8, DHX15, CDC40, PRPF18, TRA2A, SFRS2, PRPF19 | More | | | Buprenorphine | hsa03060 | Protein export | 3.28E-02 | 1 | Q15070 | OXA1L | More | | | Buprenorphine | hsa04015 | Rap1 signaling pathway | 1.58E-02 | 6 | P20827, P49767, P63261, P25116, P0DP23, P17252 | EFNA1, VEGFC, ACTG1, F2R, CALM1, PRKCA | More | | | Buprenorphine | hsa04020 | Calcium signaling pathway | 1.16E-03 | 7 | Q16566, P17252, O15399, P25116, P0DP23, P23634, P49767 | CAMK4, PRKCA, GRIN2D, F2R, CALM1, ATP2B4, VEGFC | More | | | Buprenorphine | hsa04022 | cGMP-PKG signaling pathway | 2.55E-02 | 4 | P18848, Q8WYR1, P05141, P0DP24 | ATF4, PIK3R5, SLC25A5, CALM2 | More | | | Buprenorphine | hsa04024 | cAMP signaling pathway | 2.84E-02 | 5 | P0DP23, P23634, Q16566, O15399, P25116 | CALM1, ATP2B4, CAMK4, GRIN2D, F2R | More | | | Buprenorphine | hsa04060 | Cytokine-cytokine receptor interaction | 1.74E-02 | 7 | Q9UHF4, P16871, Q9UBD3, P47992, P02775, P32248, P51684 | IL20RA, IL7R, XCL2, XCL1, PPBP, CCR7, CCR6 | More | | | Buprenorphine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 7.74E-04 | 6 | P51684, P32248, P02775, P47992, Q9UBD3, Q9UHF4 | CCR6, CCR7, PPBP, XCL1, XCL2, IL20RA | More | | | Buprenorphine | hsa04062 | Chemokine signaling pathway | 3.93E-03 | 10 | P25024, P25025, P47992, Q9UBD3, P07948, P63218, P50151, P49407, Q08881, P49841 | CXCR1, CXCR2, XCL1, XCL2, LYN, GNG5, GNG10, ARRB1, ITK, GSK3B | More | | | Buprenorphine | hsa04064 | NF-kappa B signaling pathway | 4.92E-02 | 6 | P10415, P51617, Q13546, Q9UDY8, Q13077, P24522 | BCL2, IRAK1, RIPK1, MALT1, TRAF1, GADD45A | More | | | Buprenorphine | hsa04066 | HIF-1 signaling pathway | 3.40E-02 | 3 | Q09472, P07195, P10415 | EP300, LDHB, BCL2 | More | | | Buprenorphine | hsa04070 | Phosphatidylinositol signaling system | 4.07E-02 | 4 | P0DP23, Q14643, O14732, P17252 | CALM1, ITPR1, IMPA2, PRKCA | More | | | Buprenorphine | hsa04071 | Sphingolipid signaling pathway | 1.81E-05 | 10 | P17252, P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, Q16539, P04637, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, MAPK14, TP53, BCL2 | More | | | Buprenorphine | hsa04110 | Cell cycle | 2.06E-02 | 6 | Q9UJX4, O60566, Q09472, P24522, P04637, P49918 | ANAPC5, BUB1B, EP300, GADD45A, TP53, CDKN1C | More | | | Buprenorphine | hsa04145 | Phagosome | 1.06E-03 | 11 | O75015, P63261, Q15080, Q13509, P68371, Q13488, P05164, O60603, P35443, P27824, P13765 | FCGR3B, ACTG1, NCF4, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, CANX, HLA-DOB | More | | | Buprenorphine | hsa04151 | PI3K-Akt signaling pathway | 7.39E-03 | 7 | P62753, O43521, P27348, Q8WYR1, P18848, O00141, Q6ZUJ8 | RPS6, BCL2L11, YWHAQ, PIK3R5, ATF4, SGK, PIK3AP1 | More | | | Buprenorphine | hsa04152 | AMPK signaling pathway | 2.34E-02 | 2 | Q96EB6, P36956 | SIRT1, SREBF1 | More | | | Buprenorphine | hsa04210 | Apoptosis | 2.44E-04 | 10 | P04637, P10415, O75460, P24522, Q13077, O43521, P43234, Q9UBR2, P18848, Q14643 | TP53, BCL2, ERN1, GADD45A, TRAF1, BCL2L11, CTSO, CTSZ, ATF4, ITPR1 | More | | | Buprenorphine | hsa04217 | Necroptosis | 5.66E-03 | 5 | P15104, P05141, P01584, P0C0S5, Q9H444 | GLUL, SLC25A5, IL1B, H2AFZ, CHMP4B | More | | | Buprenorphine | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.44E-02 | 5 | Q16537, P0DP23, P17252, P10415, P20020 | PPP2R5E, CALM1, PRKCA, BCL2, ATP2B1 | More | | | Buprenorphine | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | | Buprenorphine | hsa04390 | Hippo signaling pathway | 1.47E-02 | 5 | P63261, Q13485, Q9UJU2, O43623, Q13489 | ACTG1, SMAD4, LEF1, SNAI2, BIRC3 | More | | | Buprenorphine | hsa04510 | Focal adhesion | 3.21E-02 | 6 | Q15942, P17252, Q13489, P10415, P49767, P63261 | ZYX, PRKCA, BIRC3, BCL2, VEGFC, ACTG1 | More | | | Buprenorphine | hsa04520 | Adherens junction | 3.36E-02 | 4 | Q13485, Q9UJU2, O43623, P63261 | SMAD4, LEF1, SNAI2, ACTG1 | More | | | Buprenorphine | hsa04540 | Gap junction | 4.76E-02 | 3 | P17252, Q13509, P68371 | PRKCA, TUBB3, TUBB2C | More | | | Buprenorphine | hsa04612 | Antigen processing and presentation | 1.51E-02 | 7 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A | More | | | Buprenorphine | hsa04613 | Neutrophil extracellular trap formation | 6.02E-04 | 15 | P17252, O60603, P05164, P08246, Q9UM07, Q92769, Q6FI13, P33778, P14598, Q15080, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, HDAC2, H2AC18; H2AC19, H2BC3, NCF1, NCF4, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | | Buprenorphine | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | | Buprenorphine | hsa04650 | Natural killer cell mediated cytotoxicity | 7.01E-05 | 10 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | | Buprenorphine | hsa04660 | T cell receptor signaling pathway | 1.49E-03 | 10 | P01375, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | | Buprenorphine | hsa04666 | Fc gamma R-mediated phagocytosis | 2.22E-02 | 4 | P49006, P06396, P14598, P17252 | MARCKSL1, GSN, NCF1, PRKCA | More | | | Buprenorphine | hsa04668 | TNF signaling pathway | 2.91E-02 | 3 | P18848, P01584, P20333 | ATF4, IL1B, TNFRSF1B | More | | | Buprenorphine | hsa04720 | Long-term potentiation | 3.70E-04 | 5 | P17252, Q16566, P0DP23, O15399, Q14643 | PRKCA, CAMK4, CALM1, GRIN2D, ITPR1 | More | | | Buprenorphine | hsa04723 | Retrograde endocannabinoid signaling | 1.75E-02 | 5 | Q14643, P17252, P22694, Q16539, Q16718 | ITPR1, PRKCA, PRKACB, MAPK14, NDUFA5 | More | | | Buprenorphine | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | | | Buprenorphine | hsa04912 | GnRH signaling pathway | 3.80E-04 | 6 | P17252, Q16539, Q9Y6R4, Q14643, P0DP23, P22694 | PRKCA, MAPK14, MAP3K4, ITPR1, CALM1, PRKACB | More | | | Buprenorphine | hsa04916 | Melanogenesis | 3.55E-02 | 3 | P0DP23, Q9UJU2, P17252 | CALM1, LEF1, PRKCA | More | | | Buprenorphine | hsa04921 | Oxytocin signaling pathway | 4.19E-02 | 4 | P0DP23, P17252, Q16566, P63261 | CALM1, PRKCA, CAMK4, ACTG1 | More | | | Buprenorphine | hsa04925 | Aldosterone synthesis and secretion | 2.90E-04 | 6 | Q14643, P0DP23, P17252, Q16566, P20020, P23634 | ITPR1, CALM1, PRKCA, CAMK4, ATP2B1, ATP2B4 | More | | | Buprenorphine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.75E-02 | 5 | Q14643, P22694, P23771, P17252, P10415 | ITPR1, PRKACB, GATA3, PRKCA, BCL2 | More | | | Buprenorphine | hsa04932 | Non-alcoholic fatty liver disease | 2.05E-03 | 5 | O43521, P18848, O75460, P01584, P13073 | BCL2L11, ATF4, ERN1, IL1B, COX4I1 | More | | | Buprenorphine | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.36E-02 | 4 | Q13485, P10415, P49767, P17252 | SMAD4, BCL2, VEGFC, PRKCA | More | | | Buprenorphine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.88E-02 | 1 | P49448 | GLUD2 | More | | | Buprenorphine | hsa04966 | Collecting duct acid secretion | 3.15E-02 | 2 | P02730, Q9Y666 | SLC4A1, SLC12A7 | More | | | Buprenorphine | hsa04970 | Salivary secretion | 8.71E-04 | 5 | Q14643, P20020, P23634, P17252, P0DP23 | ITPR1, ATP2B1, ATP2B4, PRKCA, CALM1 | More | | | Buprenorphine | hsa04971 | Gastric acid secretion | 4.76E-02 | 3 | P17252, P63261, P0DP23 | PRKCA, ACTG1, CALM1 | More | | | Buprenorphine | hsa04972 | Pancreatic secretion | 1.00E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | | Buprenorphine | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | | Buprenorphine | hsa05010 | Alzheimer disease | 2.78E-02 | 6 | P13073, O75460, P0DP24, P01584, P18848, P05141 | COX4I1, ERN1, CALM2, IL1B, ATF4, SLC25A5 | More | | | Buprenorphine | hsa05012 | Parkinson disease | 3.89E-02 | 5 | P13073, P05141, O75460, P18848, P0DP24 | COX4I1, SLC25A5, ERN1, ATF4, CALM2 | More | | | Buprenorphine | hsa05014 | Amyotrophic lateral sclerosis | 4.31E-02 | 7 | O15399, P10415, Q13509, P68371, Q53GS7, P63261, Q9GZY0 | GRIN2D, BCL2, TUBB3, TUBB2C, GLE1, ACTG1, NXF2; NXF2B | More | | | Buprenorphine | hsa05016 | Huntington disease | 4.87E-02 | 5 | P13073, P24928, P62487, P05141, O75460 | COX4I1, POLR2A, POLR2G, SLC25A5, ERN1 | More | | | Buprenorphine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.98E-02 | 7 | P13073, O75460, P18848, P05141, P20333, P01584, P0DP24 | COX4I1, ERN1, ATF4, SLC25A5, TNFRSF1B, IL1B, CALM2 | More | | | Buprenorphine | hsa05031 | Amphetamine addiction | 1.49E-02 | 4 | O15399, P0DP23, Q16566, P17252 | GRIN2D, CALM1, CAMK4, PRKCA | More | | | Buprenorphine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.11E-02 | 4 | Q16539, P25024, P25025, P07948 | MAPK14, CXCR1, CXCR2, LYN | More | | | Buprenorphine | hsa05132 | Salmonella infection | 2.12E-04 | 13 | P51617, Q9UJU2, P63261, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509, P68371 | IRAK1, LEF1, ACTG1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3, TUBB2C | More | | | Buprenorphine | hsa05133 | Pertussis | 2.52E-02 | 3 | P0DP23, P23528, P09871 | CALM1, CFL1, C1S | More | | | Buprenorphine | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | | Buprenorphine | hsa05140 | Leishmaniasis | 1.56E-02 | 5 | P14598, O60603, P49006, P51617, Q15080 | NCF1, TLR2, MARCKSL1, IRAK1, NCF4 | More | | | Buprenorphine | hsa05144 | Malaria | 1.64E-03 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | | Buprenorphine | hsa05152 | Tuberculosis | 1.26E-02 | 8 | Q13488, O75015, P48382, O60603, P10415, P13765, Q9UDY8, Q16539 | TCIRG1, FCGR3B, RFX5, TLR2, BCL2, HLA-DOB, MALT1, MAPK14 | More | | | Buprenorphine | hsa05163 | Human cytomegalovirus infection | 1.72E-02 | 8 | P01375, P63218, P50151, P49841, P14778, P25025, Q16539, O00463 | TNF, GNG5, GNG10, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | | | Buprenorphine | hsa05168 | Herpes simplex virus 1 infection | 1.94E-02 | 9 | Q9UKJ0, P01568, Q9GZY0, Q01130, Q13489, Q13398, Q03923, Q9UDV6, P10415 | PILRB, IFNA21, NXF2; NXF2B, SFRS2, BIRC3, ZNF211, ZNF85, ZNF212, BCL2 | More | | | Buprenorphine | hsa05169 | Epstein-Barr virus infection | 2.15E-03 | 10 | P13765, Q92769, P04637, Q13546, P10415, P24522, O60603, P29728, P51617, P09693 | HLA-DOB, HDAC2, TP53, RIPK1, BCL2, GADD45A, TLR2, OAS2, IRAK1, CD3G | More | | | Buprenorphine | hsa05170 | Human immunodeficiency virus 1 infection | 6.54E-03 | 9 | P0DP23, P17252, Q13546, Q14643, P51617, O60603, P09693, P10415, Q9Y6Q5 | CALM1, PRKCA, RIPK1, ITPR1, IRAK1, TLR2, CD3G, BCL2, AP1M2 | More | | | Buprenorphine | hsa05200 | Pathways in cancer | 2.37E-03 | 18 | P04637, Q9UJU2, P17252, Q09472, P43246, Q13485, P14923, P10415, Q13489, Q13077, P49767, P25116, O95267, P78417, P24522, P0DP23, P01568, P16871 | TP53, LEF1, PRKCA, EP300, MSH2, SMAD4, JUP, BCL2, BIRC3, TRAF1, VEGFC, F2R, RASGRP1, GSTO1, GADD45A, CALM1, IFNA21, IL7R | More | | | Buprenorphine | hsa05202 | Transcriptional misregulation in cancer | 1.91E-04 | 16 | Q12778, Q15532, P41732, P14780, P27930, P14923, Q16548, Q13489, Q13077, O15550, P04637, P35226, P05164, P08246, Q9C0K0, P24522 | FOXO1, SS18, TSPAN7, MMP9, IL1R2, JUP, BCL2A1, BIRC3, TRAF1, UTX, TP53, BMI1, MPO, ELA2, BCL11B, GADD45A | More | | | Buprenorphine | hsa05210 | Colorectal cancer | 2.41E-02 | 4 | P10415, P04637, Q9UJU2, P24522 | BCL2, TP53, LEF1, GADD45A | More | | | Buprenorphine | hsa05212 | Pancreatic cancer | 3.40E-02 | 1 | P37173 | TGFBR2 | More | | | Buprenorphine | hsa05213 | Endometrial cancer | 1.91E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | | Buprenorphine | hsa05214 | Glioma | 8.71E-04 | 5 | P0DP23, Q16566, P17252, P04637, P24522 | CALM1, CAMK4, PRKCA, TP53, GADD45A | More | | | Buprenorphine | hsa05215 | Prostate cancer | 1.94E-02 | 4 | P10415, Q9UJU2, Q09472, P04637 | BCL2, LEF1, EP300, TP53 | More | | | Buprenorphine | hsa05216 | Thyroid cancer | 2.42E-04 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | | Buprenorphine | hsa05217 | Basal cell carcinoma | 1.56E-03 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | | Buprenorphine | hsa05222 | Small cell lung cancer | 1.94E-02 | 4 | P10415, Q13077, P04637, P24522 | BCL2, TRAF1, TP53, GADD45A | More | | | Buprenorphine | hsa05224 | Breast cancer | 4.32E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | | Buprenorphine | hsa05226 | Gastric cancer | 8.86E-03 | 5 | Q9UJU2, P04637, P24522, P14923, P10415 | LEF1, TP53, GADD45A, JUP, BCL2 | More | | | Buprenorphine | hsa05230 | Central carbon metabolism in cancer | 4.04E-02 | 2 | P07195, P04637 | LDHB, TP53 | More | | | Buprenorphine | hsa05321 | Inflammatory bowel disease | 3.69E-02 | 4 | O60603, P13765, Q14765, P23771 | TLR2, HLA-DOB, STAT4, GATA3 | More | | | Buprenorphine | hsa05332 | Graft-versus-host disease | 1.32E-02 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | | | Buprenorphine | hsa05418 | Fluid shear stress and atherosclerosis | 2.49E-03 | 11 | Q16539, P78417, P10599, P14780, P01375, P63261, P10415, P14778, P27930, P0DP23, Q92974 | MAPK14, GSTO1, TXN, MMP9, TNF, ACTG1, BCL2, IL1R1, IL1R2, CALM1, ARHGEF2 | More | |
|
